Meet The European VCs Investing in Biotech
In December 2025, the European Commission and EIB Group announced an investment initiative of €10 billion targeting Europe's biotechnology sector. The objective is to enhance Europe's position in the global biotech industry by fostering investment in new…
In December 2025, the European Commission and EIB Group announced an investment initiative of €10 billion targeting Europe's biotechnology sector. The objective is to enhance Europe's position in the global biotech industry by fostering investment in new biotechnological discoveries and developments.
The biotech sector has experienced significant growth in recent years. The UK's biotech industry raised £3.5 billion in 2024, marking a 94% increase from the previous year. Across Europe, funding in the biotech sector reached a record €4.7 billion.
Biotechnology, often referred to as biotech, involves utilizing or modifying living organisms for human benefit. This includes advancements such as genetic engineering, development of disease-resistant crops, and creation of new vaccines.
Several European venture capital firms are investing in the biotech industry, each with a focus on innovative scientific developments that have the potential to improve human life.
V-Bio Ventures, located in Belgium, invests in early to mid-stage biotech companies with high growth potential. The firm's primary goal is to leverage scientific innovation to develop products that positively impact lives.
In December 2025, the European Commission and EIB Group announced an investment initiative of €10 billion targeting Europe's biotechnology sector.
AdBio Partners, a French venture capital firm, concentrates on early-stage biotech ventures across Europe, specifically targeting companies engaged in groundbreaking medical discoveries.
Sofinnova Partners, based in Paris, invests in early-stage companies applying biotechnology to sectors such as food, farming, chemicals, and materials. The firm has invested in over 118 companies, with more than 55 IPOs and over 30 mergers and acquisitions.
Ysios Capital, a Spanish life sciences investor, supports biotech companies through various funds. The firm focuses on investments that positively impact patients and society, having backed 42 private and public biotech companies to date.
Nina Capital is a Barcelona-based VC firm investing in companies at the intersection of healthcare and technology. The firm focuses on data-driven businesses across Europe, the US, Israel, Canada, and Australia, primarily in pre-seed to seed stages.
Redalpine, located in Zurich, invests in biotech, healthtech, and ICT companies. The firm seeks businesses that combine software and science to address global challenges.
Bpifrance, the French sovereign wealth fund and public investment bank, supports economic growth through various biotech funds. These include Innovio, Innobio 2, The Rare Diseases Fund, The Medtech Innovation Fund, and Patient Autonome.
Based on reporting by techround.co.uk.